Goldstein, Daniel 2019-04-16 Final Played in Court

Goldstein, Daniel 11-16-2017 Goldstein, Daniel 11-17-2017

Total Time 00:13:51



GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court		
Page/Line	Source	ID
11:7 - 12:5	Goldstein, Daniel 11-16-2017 (00:00:56)	GD2017.1
	11:7 Could you please state and spell your	
	11:8 full name for the record, sir?	
	11:9 A. It's Daniel A. Goldstein,	
	11:10 G-o-l-d-s-t-e-i-n.	
	11:11 Q. Great. And you understand that you	
	11:12 are under oath, right, Mr. Goldstein?	
	11:13 A. I do.	
	11:14 Q. What's your understanding of that	
	11:15 oath?	
	11:16 A. My understanding is that I am sworn	
	11:17 to tell the truth to the best of my knowledge.	
	11:18 Q. And what is your current position at	
	11:19 Monsanto?	
	11:20 A. I am a Distinguished Science Fellow	
	11:21 and Lead for Medical Sciences and Outreach at	
	11:22 Monsanto.	
	11:23 Q. What does that mean?	
	11:24 A. It means I serve several roles	
	11:25 internally as a scientist. It means I have	
	12:1 responsibility in my own particular case for	
	12:2 product safety across all of our various product	
	12:3 lines, and I am also involved in outreach and	
	12:4 communications, primarily to medical and	
	12:5 professional organizations regarding our products.	
12:19 - 13:10	Goldstein, Daniel 11-16-2017 (00:00:44)	GD2017.2
	12:19 Q. (BY MR. ESFANDIARY) Okay. What	
	12:20 training or education do you have that allows you	
	12:21 to hold the position that you currently hold at	
	12:22 Monsanto?	
	12:23 A. I have an undergraduate degree in	
	12:24 molecular biology from the University of Wisconsin.	
	12:25 I did graduate work there in the field of genetics	
	13:1 but did not receive a graduate degree. Instead I	
	13:2 went on to medical school, Johns Hopkins	
	13:3 University, completed a residency in pediatrics at	
	13:4 Johns Hopkins and then moved on to Sick Children's	
	13:5 Hospital in Toronto, where I did a fellowship in	
	13:6 clinical pharmacology and toxicology.	
	13:7 Q. So you do have specific training with	

Plaintiff Designations Monsanto Designations Page 2/10

	GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court	
Page/Line	Source	ID
	13:8 respect to toxicology?	
	13:9 A. I have training specific to medical	
	13:10 toxicology. That is correct.	
13:11 - 13:17	Goldstein, Daniel 11-16-2017 (00:00:19)	GD2017.3
	13:11 Q. Okay. And is medical toxicology, is	
	13:12 that like a is it subsumed under the general	
	13:13 umbrella of toxicology?	
	13:14 A. Medical toxicology is an official	
	13:15 specialty of medicine, like gastroenterology or	
	13:16 neurology would be. So it is a board certified	
	13:17 field of of medical study.	
13:18 - 14:1	Goldstein, Daniel 11-16-2017 (00:00:21)	GD2017.4
	13:18 Q. Okay. And do you have any training	
	13:19 as it relates to epidemiology?	
	13:20 A. I have a great deal of training as to	
	13:21 epidemiology and statistics, but I do not consider	
	13:22 myself to be an epidemiologist per se.	
	13:23 Q. Okay. You understand that Monsanto	
	13:24 has selected you to represent the company for the	
	13:25 purposes of this deposition; correct?	
	14:1 A. Yes.	
269:6 - 269:21	Goldstein, Daniel 11-17-2017 (00:00:47)	GD2017.5
	269:6 Q. (BY MR. ESFANDIARY) Dr. Goldstein,	
	269:7 these well, first of all, the Bates number on	GD16.1
	269:8 the bottom right-hand corner of this document is	
	269:9 MONGLY00885870, and this was produced by Monsanto	
	269:10 Company in this litigation. And the date of the	074044
	269:11 document is July 22, 1997, and it is addressed To	GD16.1.1
	269:12 the Communications Subcommittee, and the signatore	
	269:13 right there is John Acquavella.	
	269:14 You know Dr. Acquavella, correct, Dr.	
	269:15 Goldstein?	
	269:16 A. Yes, I do.	
	269:17 Q. And he is an epidemiologist; correct?	
	269:18 A. That is correct.	
	269:19 Q. Do you consider him a respectable	
	269:20 epidemiologist?	
270:19 - 271:10	269:21 A. Yes.	GD2017.6
210.18-2/1.10	Goldstein, Daniel 11-17-2017 (00:00:36)	clear
	270:19 Q. (BY MR. ESFANDIARY) Sure. And Dr.	Jicai

Plaintiff Designations Monsanto Designations Page 3/10

GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court			
Page/Line	Source	ID	
	270:20 Acquavella, and this might be a bit before your		
	270:21 time in 1997, but he was an employee of Monsanto at		
	270:22 the time?		
	270:23 A. Yes, he would have been.		
	270:24 Q. Okay. And he is no longer an		
	270:25 employee, is he, sir?		
	271:1 A. That's correct.		
	271:2 Q. Yeah. He still consults for Monsanto		
	271:3 on kind of an ad hoc basis?		
	271:4 A. For a number of years he did not. He		
	271:5 was employed elsewhere and wasn't available for		
	271:6 consultation. He retired about two years ago and		
	271:7 has been doing some consulting work.		
	271:8 Q. Okay. And did you work closely with		
	271:9 Dr. Acquavella when he was at Monsanto?		
	271:10 A. Yes, I did.		
271:16 - 272:3	Goldstein, Daniel 11-17-2017 (00:00:31)	GD2017.7	
	271:16 Q. Can I ask you, first of all, what the		
	271:17 Communications Subcommittee is? Is that a part of		
	271:18 Monsanto?		
	271:19 A. No, it is a part of Crop Life.		
	271:20 Q. Crop Life?		
	271:21 A. Yes.		
	271:22 Q. And what is Crop Life, sir?		
	271:23 A. Crop Life is an industry organization		
	271:24 that consists, its membership consists of pesticide		
	271:25 manufacturers and merchandisers.		
	272:1 Q. Okay. And obviously Monsanto is a		
	272:2 member of Crop Life; correct?		
	272:3 A. Yes, that is correct.		
276:20 - 277:6	Goldstein, Daniel 11-17-2017 (00:00:00)	GD2017.8	
	276:20 Q. (BY MR. ESFANDIARY) Sure. All		
	276:21 right. Well, back to the fun stuff.		
	276:22 Dr. Goldstein, if you could please		
	276:23 turn your attention to the page ending in Bates		
	276:24 number 871?		
	276:25 A. I need to look at the document for a		
	277:1 moment.		
	277:2 Q. Oh, please, yeah.		
	277:3 A. We have been talking about the		

Plaintiff Designations Monsanto Designations Page 4/10

GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court		
Page/Line	Source	ID
	077.4 be alreaded of it but I become actually leaded at	
	277:4 background of it, but I haven't actually looked at 277:5 the document.	
	277:6 Q. Sure.	
277:7 - 277:7	Goldstein, Daniel 11-17-2017 (00:00:01)	GD2017.9
21111	277:7 A. Okay.	5.2257715
277:8 - 277:18	Goldstein, Daniel 11-17-2017 (00:00:28)	GD2017.10
2	277:8 Q. Actually, if you turn your attention	GD16.1
	277:9 to the first page, the front, yeah, the face, and	
	277:10 if you look at the first paragraph of Dr.	
	277:10 if you look at the first paragraph of Dr. 277:11 Acquavella's comment there, it says, "At your last	GD16.1.2
	277:11 Acquavella's comment there, it says, 'At your last'	
	277:13 thoughts on Epidemiology and the Agricultural	
	277:14 Health Study (AHS) that you could use to build	
	277:14 Treatit Study (ATIS) that you could use to build 277:15 positive messages. Please find some preliminary	
	277:16 thoughts attached."	
	277:17 Did I read that correctly, sir?	
	277:18 A. Yes.	
278:1 - 278:9	Goldstein, Daniel 11-17-2017 (00:00:35)	GD2017.11
	278:1 Q. (BY MR. ESFANDIARY) Okay. If you	
	278:2 turn your attention to page 871. And about halfway	GD16.2
	278:3 down the section titled The AHS rationale, Dr.	
	278:4 Acquavella says, "But, the viability and eventual	GD16.2.1
	278:5 impact of the AHS will depend on the investigators'	
	278:6 ability to generate a new class of scientific	
	278:7 leads, most of which will be invalid."	
	278:8 Did I read that correctly, sir?	
	278:9 A. Yes, you did.	
278:13 - 278:19	Goldstein, Daniel 11-17-2017 (00:00:13)	GD2017.12
	278:13 Q. (BY MR. ESFANDIARY) And then right	
	278:14 after that, Dr. Acquavella says, "This has the	
	278:15 potential to be disruptive for the agricultural	
	278:16 chemical industry as new leads potentially take on	
	278:17 a life of their own."	
	278:18 Did I read that correctly, sir?	
	278:19 A. Yes, you did.	
278:21 - 278:22	Goldstein, Daniel 11-17-2017 (00:00:03)	GD2017.13
	278:21 Q. (BY MR. ESFANDIARY) And what is your	
	278:22 understanding of what I've just read to you?	
279:1 - 280:15	Goldstein, Daniel 11-17-2017 (00:02:32)	GD2017.14
	279:1 A. So this is essentially what I was	

Plaintiff Designations Monsanto Designations Page 5/10

Page/Line	Source	ID
	279:2 saying previously. This is a study that is not	
	279:3 simply investigating one specific question. It is	
	279:4 a study that, over a long period of time, is	
	279:5 looking at many different questions, and it falls	
	279:6 into the category of what we would call exploratory	ala an
	279:7 epidemiology.	clear
	279:8 The problem you have with exploratory	
	279:9 epidemiology is that you're going to find a	
	279:10 significant number of statistical associations that	
	279:11 don't represent cause and effect. They're just due	
	279:12 to to statistical variation and the fact that	
	279:13 you're doing multiple types of testing.	
	279:14 And unfortunately, it's not just	
	279:15 agriculture. The public has ended up in in a	
	279:16 sea of these hypotheses of, you know, that Tylenol	
	279:17 causes asthma. You know, coffee and abortion.	
	279:18 These are all statistical associations from studies	
	279:19 that are not designed to test anything specific.	
	279:20 They're just looking for associations. They give	
	279:21 you an idea what may be true, but they have very	
	279:22 little ability to discern what is correct.	
	279:23 And that's the problem he's referring	
	279:24 to here. We know that exposures to pesticides are	
	279:25 low. We know that the vast majority of them have	
	280:1 been extensively tested for their carcinogenicity.	
	280:2 Their their exposures are limited by label	
	280:3 instructions and by by practices.	
	280:4 So looking at what we know about risk	
	280:5 of cancer relative to exposure, you shouldn't	
	280:6 expect to be able to find anything in the Ag Health	
	280:7 Study. And what John Acquavella is saying is	
	280:8 precisely correct. The vast majority of the	
	280:9 findings in the Ag Health Study are going to be	
	280:10 spurious statistical associations that will not	
	280:11 replicate themselves over time.	
	280:12 Q. (BY MR. ESFANDIARY) Okay. But you	
	280:13 agree with me, sir, that there's a difference	
	280:14 between coffee and abortion, and pesticides and	
000-40 000-40	280:15 cancer; right?	CD0047.45
280:18 - 280:19	Goldstein, Daniel 11-17-2017 (00:00:03)	GD2017.15

GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court

Plaintiff Designations Monsanto Designations Page 6/10

	GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court	
Page/Line	Source	ID
	280:18 A. I'm going to have to have a more	
	280:19 specific question than that.	
281:2 - 281:11	Goldstein, Daniel 11-17-2017 (00:00:26)	GD2017.16
	281:2 Q. (BY MR. ESFANDIARY) That's fine,	
	281:3 Doctor, I'll I'll explain. So earlier in your	
	281:4 answer you said that the public is kind of, you	
	281:5 know, in the midst of this miasma of, you know,	
	281:6 unwarranted concern because you have statistical	
	281:7 associations between coffee and abortion and you	
	281:8 equated that with, you know, what Dr. Acquavella is	
	281:9 apparently saying about the AHS and I'm wondering	
	281:10 whether coffee and abortion, in your eyes, are the	
	281:11 same as pesticide exposure and cancer.	
281:15 - 281:24	Goldstein, Daniel 11-17-2017 (00:00:25)	GD2017.17
	281:15 A. The same in what regard? If you have	
	281:16 two false epidemiological studies, they're both	
	281:17 false epidemiological studies and they're giving	
	281:18 bad information to the public.	
	281:19 Q. (BY MR. ESFANDIARY) Let me put it in	
	281:20 scientific terms. There is a plausible causal	
	281:21 association between pesticides, certain pesticides	
	281:22 and cancer; whereas, there is no plausible causal	
	281:23 association between coffee and abortion, is there,	
	281:24 sir?	
282:4 - 282:11	Goldstein, Daniel 11-17-2017 (00:00:21)	GD2017.18
	282:4 A. You're incorrect. The perfectly	
	282:5 plausible explanation for why you might see	
	282:6 increased risk of spontaneous abortion with	
	282:7 caffeine, the plausibility of cancer being related	
	282:8 to pesticides in an epidemiological study is	
	282:9 actually far less than the plausibility of the	
	282:10 hypothesis around caffeine and spontaneous	
0044 00440	282:11 abortion.	CD0047.40
284:4 - 284:13	Goldstein, Daniel 11-17-2017 (00:00:30)	GD2017.19
	284:4 Q. Okay. And Dr. Acquavella says, "Most	GD16.3.1
	284:5 of the diseases to be studied in the AHS have scant	
	284:6 reasoning to link them putatively to pesticide	
	284:7 exposure. Thus, much of the research can be termed	
	284:8 'exploratory.' That's not unusual in epidemiology,	
	284:9 but it is unusual on this big a scale."	

Plaintiff Designations Monsanto Designations Page 7/10

	GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court	
Page/Line	Source	ID
	284:10 And my question to you is, sir, do	
	284:11 you agree that the AHS broke with established	
	284:12 epidemiological principles by embarking on a large	
284:17 - 284:17	284:13 exploratory cohort study?	GD2017.20
204.17 - 204.17	Goldstein, Daniel 11-17-2017 (00:00:02)	GD2017.20
284:20 - 285:12	284:17 A. No, I don't.	GD2017.21
204.20 - 200.12	Goldstein, Daniel 11-17-2017 (00:01:07)	GD2017.21
	284:20 Okay. If you turn your attention to	GD16.4
	284:21 page ending in Bates number 873? Okay. And at the	GD10.4
	284:22 top of the page there in the section titled	GD16.4.1
	284:23 Exposure assessment, Dr. Acquavella says, "The	GD 10.4.1
	284:24 exposure assessment in the AHS will be inaccurate.	
	284:25 Exposure assessment will be based on historical	
	285:1 usage as reported by the farmer or applicator on	
	285:2 the study questionnaire(s). There are two problems	
	285:3 with this approach: 1. usage does not necessarily	
	285:4 mean exposure (work practices/equipment/	
	285:5 environmental conditions determine exposure to a	
	285:6 large degree); 2. recall can be faulty or biased,	
	285:7 especially when historical usage information is 285:8 collected. Attempts on verification over a 3 year	
	285:9 period have found less than 70 percent agreement	
	285:10 between purchasing records and reported usage." 285:11 Did I read that correctly, sir?	
	285:12 A. Yes, you did.	
285:16 - 285:17	Goldstein, Daniel 11-17-2017 (00:00:02)	GD2017.22
	285:16 Q. (BY MR. ESFANDIARY) Dr. Goldstein,	
	285:17 do you agree with this assessment?	
285:20 - 285:20	Goldstein, Daniel 11-17-2017 (00:00:00)	GD2017.23
	285:20 A. Yes, I do.	clear
337:13 - 338:7	Goldstein, Daniel 11-17-2017 (00:00:55)	GD2017.24
	337:13 Q. Good afternoon, Dr. Goldstein. My	
	337:14 name is Gary Rubin, as you know, and I represent	
	337:15 Monsanto in this litigation. I just have a few	
	337:16 follow-up questions to ask. Same rules, if you	
	337:17 don't understand my question, please ask me to	
	337:18 explain it, I'll be happy to.	
	337:19 Dr. Goldstein, over the past two days	
	337:20 you have been asked a number of questions about	
	337:21 what we've called the AHS; is that correct?	

Plaintiff Designations Monsanto Designations Page 8/10

	GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court	
Page/Line	Source	ID
	337:22 A. Yes.	
	337:23 Q. Okay. Can you tell the jury what the	
	337:24 AHS is, please?	
	337:25 A. So the Agricultural Health Study, or	
	•	
	338:1 AHS, is the largest study of farmers and pesticide	
	338:2 applicators and their health that has ever been	
	338:3 undertaken. It is performed by the National Cancer	
	338:4 Institute and has been going on now for nearly 25	
	338:5 years.	
	338:6 Q. Would you consider it a robust study? 338:7 A. It is	
338:9 - 338:25		GD2017.25
000.0 000.20	Goldstein, Daniel 11-17-2017 (00:00:41)	5.2201,120
	338:9 A. It is an extremely robust study. I	
	338:10 would consider it to be the most robust and	
	338:11 reliable data set that we have available.	
	338:12 Q. (BY MR. RUBIN) Okay. You looked at	
	338:13 a document this morning that Plaintiffs' counsel	GD16.1
	338:14 showed you, I believe it was Exhibit 16, and I'll	GD10.1
	338:15 just give it to you to refresh your memory.	
	338:16 Do you remember looking at that	
	338:17 document?	
	338:18 A. Yes.	GD16.1.3
	338:19 Q. And that document is dated 1997?	GD10.1.3
	338:20 A. That is correct.	
	338:21 Q. Okay. You were asked questions about	
	338:22 the methodology back then. Do you remember that?	
	338:23 A. Yes.	
	338:24 Q. Has the methodology changed since	
000.0 000.5	338:25 1997?	CD0047.08
339:3 - 339:5	Goldstein, Daniel 11-17-2017 (00:00:05)	GD2017.26
	339:3 A. Yes, it has.	alaan
	339:4 Q. (BY MR. RUBIN) What is the effect of	clear
0007 0007	339:5 this change in methodology?	OD0047.00
339:7 - 339:7	Goldstein, Daniel 11-17-2017 (00:00:03)	GD2017.28
000 0 000 05	339:7 A. The improvement in exposure metrics	OD0047.07
339:8 - 339:25	Goldstein, Daniel 11-17-2017 (00:00:50)	GD2017.27
	339:8 has addressed many of the concerns that were raised	
	339:9 in the 1997 document, and so I think with that	
	339:10 improvement in exposure assessment, it just	
	339:11 reinforces the fact that this is the most reliable	

Plaintiff Designations Monsanto Designations Page 9/10

	GD2017-Goldstein, Daniel 2019-04-16 Final Played in Court	
Page/Line	Source	ID
	339:12 and robust data set available.	
	339:13 Q. (BY MR. RUBIN) Okay. Just so the	
	339:14 jury is absolutely clear, when was the most recent	
	339:15 AHS report issued?	
	339:16 A. Last week.	
	339:17 Q. Just in November of 2017?	
	339:18 A. Yes, that's correct.	
	339:19 Q. Okay. Have you had a chance to look	
	339:20 at that report and review it?	
	339:21 A. I have.	
	339:22 Q. And what did the report show?	
	339:23 A. That report showed no relationship	
	339:24 between user exposure to glyphosate and the	
	339:25 occurrence of any cancer type in humans.	
340: 1 - 340:5	Goldstein, Daniel 11-17-2017 (00:00:03)	GD2017.29
	340:1 MR. RUBIN: I have no further	
	340:2 THE WITNESS: Thank you.	
	340:3 MR. RUBIN: I have no further	
	340:4 questions for you, Dr. Goldman.	
	340:5 THE WITNESS: Thank you.	

Total Time = 00:13:51

Documents Shown GD16

Plaintiff Designations Monsanto Designations Page 10/10